Cohance Lifesciences Gears Up for Q3 Reveal on 12th February; Check Key Expectations Here

February 11, 2026
Posted by: Ekta Dhawan
Category: News

Click and Sign Up to Get Live Updates on Q3 Results

Cohance Lifesciences ‘s Q3 results FY26 are scheduled to be announced on 12th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Cohance Lifesciences Q3 Results 2026 Preview

Cohance Lifesciences’ revenue is expected to be in the range of ₹307.15 crore, a 49.13% YoY decrease.
Profit After Tax, or PAT, is projected to fall 40.15% YoY.
Net profit is ₹82.88 crore, a fall 40.15% YoY
EBITDA to fall 41.91%

Cohance Lifesciences Share Performance

Over the past six months, Cohance Lifesciences’ share price has fallen by 62.56% to ₹352.50.
Moreover, over the past year, the stock has decreased by 67.01%.
Despite this weak short-term performance, Cohance Lifesciences’ stock has delivered a financially sound 67.61% return over the past 5 years.
As of 11th February 2026, the stock traded at ₹352.60 per share.

Key Factors to Watch for Cohance Lifesciences Q3 Results FY26

Revenue & Segment Growth: Trends in overall sales and performance across CDMO and API+ businesses.
Profitability & Margins: EBITDA and net profit margins amid cost and operating pressures.
Order Execution & Project Timing: Impact of timing of CDMO project starts and shipments.
Niche Technology Demand: Growth in specialized chemistries like ADCs and oligonucleotides.
Management Outlook: Guidance on FY26 growth trajectory and long-term goals.

Final Thoughts

Cohance Lifesciences will announce its Q3 FY26 results on 12th February 2026. Analysts expect % revenue growth, a 27.3% fall in PAT, and a 18.14% rise in EBITDA. Cohance Lifesciences focuses on revenue growth, margins, order execution, high-value segment performance, and management outlook.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

GOCL Corporation Q3 Results FY26 Preview

Godrej Industries Q3 Results FY26 Preview

Godawari Power and Ispat Q3 Results FY26 Preview

Hikal Q3 Results FY26 Preview

Himatsingka Seide Q3 Results FY26 Preview

Igarashi Motors India FY26 Preview

IG Petrochemicals Ltd Q3 Results FY26 Preview

IOL Chemicals & Pharmaceuticals Q3 Results FY26 Preview

Q3 Results Q3 Results 2026

Author: Ekta Dhawan

Ekta Dhawan is a Financial Content Writer at Univest, covering Indian equity markets with a focus on stock analysis, IPOs, and quarterly earnings results. Over 2+ years, she has published 1500+ articles tracking listed companies across sectors, translating complex financial data into clear, actionable insights for retail investors. She holds a Bachelor of Business Administration (BBA) and a Post Graduate Diploma in Management (PGDM), giving her a structured grounding in corporate finance, equity valuation, and capital markets. Her writing moves past surface-level reporting to explain why a stock is moving, what a quarterly result signals, and how investors should interpret it. She also brings expertise in SEO content strategy, keyword research, and on-page optimisation, ensuring articles reach investors actively searching for clarity on market events. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.